Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Ishitsuka

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
Biochimica Et Biophysica Acta|May 24, 1988
Hemolytic activity of a cyclic peptide Ro09-0198 isolated from StreptoverticilliumS Y Choung, T Kobayashi, J Inoue, et al.
Gan|February 1, 1980
Role of uridine phosphorylase for antitumor activity of 5'-deoxy-5-fluorouridineH Ishitsuka, M Miwa, K Takemoto, et al.
Pharmaceutical Research|October 6, 2001
A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FUY Tsukamoto, Y Kato, M Ura, et al.
International Journal of Cancer|August 17, 1999
Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor modelsM Endo, N Shinbori, Y Fukase, et al.
Clinical & Experimental Metastasis|October 1, 1985
Antitumor and antimetastatic activities of human recombinant interferon alpha A/DJ Nishimura, K Mitsui, T Ishikawa, et al.
Biopharmaceutics & Drug Disposition|December 18, 2001
Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft modelY Tsukamoto, Y Kato, M Ura, et al.
Biochemical Pharmacology|May 30, 1998
Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenograftsT Ishikawa, M Utoh, N Sawada, et al.
The Journal of Antimicrobial Chemotherapy|December 1, 1987
Intranasal chalcone, Ro 09-0410, as prophylaxis against rhinovirus infection in human volunteersW Al-Nakib, P G Higgins, I Barrow, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 1, 1987
[Antitumor effects of 5'-deoxy-5-fluorouridine (5'-DFUR) against various murine tumors in combination with recombinant interferon alpha or cytostatics]Y Ninomiya, M Miwa, H Fukuda, et al.
International Journal of Oncology|May 6, 2011
Differential expression of platelet-derived endothelial cell growth factor (thymidine phosphorylase) in nonpolypoid and polypoid lesions of the colonT Saeki, S Takashima, S Hosokawa, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Biochimica Et Biophysica Acta|May 24, 1988
Hemolytic activity of a cyclic peptide Ro09-0198 isolated from StreptoverticilliumS Y Choung, T Kobayashi, J Inoue, et al.
Gan|February 1, 1980
Role of uridine phosphorylase for antitumor activity of 5'-deoxy-5-fluorouridineH Ishitsuka, M Miwa, K Takemoto, et al.
Pharmaceutical Research|October 6, 2001
A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FUY Tsukamoto, Y Kato, M Ura, et al.
International Journal of Cancer|August 17, 1999
Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor modelsM Endo, N Shinbori, Y Fukase, et al.
Clinical & Experimental Metastasis|October 1, 1985
Antitumor and antimetastatic activities of human recombinant interferon alpha A/DJ Nishimura, K Mitsui, T Ishikawa, et al.
Biopharmaceutics & Drug Disposition|December 18, 2001
Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft modelY Tsukamoto, Y Kato, M Ura, et al.
Biochemical Pharmacology|May 30, 1998
Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenograftsT Ishikawa, M Utoh, N Sawada, et al.
The Journal of Antimicrobial Chemotherapy|December 1, 1987
Intranasal chalcone, Ro 09-0410, as prophylaxis against rhinovirus infection in human volunteersW Al-Nakib, P G Higgins, I Barrow, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 1, 1987
[Antitumor effects of 5'-deoxy-5-fluorouridine (5'-DFUR) against various murine tumors in combination with recombinant interferon alpha or cytostatics]Y Ninomiya, M Miwa, H Fukuda, et al.
International Journal of Oncology|May 6, 2011
Differential expression of platelet-derived endothelial cell growth factor (thymidine phosphorylase) in nonpolypoid and polypoid lesions of the colonT Saeki, S Takashima, S Hosokawa, et al.
Pageof 7